

Cyfoeth Naturiol Cymru Natural Resources Wales

# Chemical monitoring activity under the Water Framework Directive – Analytical challenges and solutions

Anthony Gravell Natural Resources Wales Llanelli laboratory



aturiol /mru atural esources ales

#### About us

Natural Resources Wales brings together the work of the Countryside Council for Wales, Environment Agency Wales and Forestry Commission Wales, as well as some functions of Welsh Government.

Our purpose is to ensure that the natural resources of Wales are sustainably maintained, enhanced and used, now and in the future

#### Who we are and what we do

The principal adviser to the Welsh Government on the environment, enabling the sustainable development of Wales' natural resources for the benefit of people, the economy and wildlife

#### **Overview**

- Monitoring under the Water Framework Directive
- Passive Sampling
- HRAM Screening
- Confirmation of identity of pollutants in real life samples
- Summary



### WFD

- far-reaching and complex legislation for water quality across Europe
- involves the formulation of cross border River Basin Management Plans (RBMPs)
- introduces environmental quality standards (EQS) values for priority hazardous substances





### WFD challenge

- The WFD via revised Environmental Quality Standards (EQS) has driven down the required reporting limits for selected compounds to challenging concentrations analytically!
- Lower detection limits for selected compounds require high specification instruments to deliver required sensitivity
- New monitoring methods and analytical techniques are now necessary
- Further requirement to undertake **investigative** monitoring in order to identify unknown nontarget pollutants in water bodies with poor ecology or identified at risk





### **Environmental Challenge**

#### Achieving and maintaining a "Good Status"

Only 5 rivers in England & Wales meet the new tough standard or High ecological status, which looks at ecological, as well as chemical and other factors..

93% of rivers are currently classified as 'good' or 'fair' based on their chemistry. However, it is estimated that 95% of water bodies are at risk of failing to meet WFD "good status"

 Identifying all of the sources of potential pollution

♦ Estimated that 80% of work required just to stand-still

Pressures of climate change & population growth



- Pollutants can be below the limit of detection but high enough to have a chronic effect on aquatic organisms
- Current spot sampling techniques unable to detect transient events only a snapshot at time of sampling
- Therefore many compounds / pollutants will remain unidentified!
- Large errors associated with calculations of mass loadings of receiving water courses





### One novel approach - Passive sampling with HRAM screening

## Benefits of passive sampling

- passive (integrative) sampling concentrates trace levels of chemicals
- provides time-weighted average concentrations and gives realistic chemical loading levels
- detects transient changes in environmental contaminant concentrations (vs 'spot' sampling)
- applicable to almost all aqueous environmental conditions
- selectively samples residues from the dissolved (readily bio-available) phase
- allows concentration of trace, yet toxicologically relevant, contaminant mixtures over extended periods of time





### **Choice of sampler**

Chemcatcher





## **Deployment and retrieval of samplers**



POCIS samplers showing fouling after retrieval, before rinsing with distilled water Housing deployed close to river bed resulting in the deposition of silt in the protective housing





#### **Extraction of samplers**



Disks are cleaned, eluted with methanol and reduced to low volume







## Findings from a recent trial

- More than 90% of the compounds identified using a combination of passive samplers and screening methods were not identified using the routine spot sampling technique
- Also, 95% of the compounds identified using the recently developed LCMS screen were not identified using the routine GCMS Target based multi residue screen method
- Many of the substances identified by passive sampling are priority hazardous substances listed in Annex X of the Water Framework Directive
- Other compounds identified by passive sampling include the newly classified emerging contaminants such as triclosan, pharmaceuticals and sun-screen agents



#### **River Wye at Bigsweir Bridge**



Mixture of fungicides, herbicides identified by LCMS Screen not picked up by GC-MS Screen





#### **River Mersey at Woolston Weir**



Mixture of fungicides, herbicides and insecticide metabolite identified by LCMS Screen - Not picked up by GC-MS Screen





### Other polar compounds found

#### POCIS

Carbamazepine Sulfamethoxazole Oxprenolol Atenolol Sotalol Trimethoprim Ibuprofen PFHS PFOA

PFOS

Mixture of pharmaceuticals inc. analgesics, anti-biotics, beta blockers plus persistent fluorinated compounds





## **Screening for pharmaceuticals**

- Pharmaceuticals now included in WFD
- Most work undertaken by LCMS QQQ
- Database of pharmaceuticals developed based on top 200 prescribed pharmaceuticals in England & Wales
- POCIS extracts run on Q-Exactive
- 39 compounds specifically interested in due to matrix interferences on lower resolution instrument



## Irbesartan in sample extract

Therea TooleFinder SPS 10															1/14		
a Vere Jack Helr ) S G (11) 1 Helr		4 4 0 B	203													ol troe ctatue   Unex alon	1000.100
nalysis 🔹 🕈	Data Review - Plan	CHARLENCE AND INCOME.															
Butch View	Corporate	* 1	- 54	riple Results								_					• •
- and a second	P Compound	Expected IF	1 10	Fierane	Areo	Formale	Antiet	miz (Expected)	m/z (Apexi	m/c (Detalppri))	Active	Excluded	PK.	F	Centim	Botapic Pottern Score	no herito
Samples	y +	5 .		5 .	5 -	8 1	p. +	5 *	5 .	5 .	×		de	5 1	de =		·
Auto Semples	25 Flumentine	18.16	1	Pharma, Rik, 1d	191626	C25H20N80	M+H	429-23918	4793-0011	0.86735	2						100 1 df3
Haforence Sample	27 Servaine	1671	2	Pharma_Bik_15	746366	C25H28N60	M+H	429.23974	42924008	079625	12	121					100 J of 3
Threshold Samples	38 Tectinatine	15.99	5	Pharma_SamUA_18	131841243	C/3H28960	M-H	429.29914	42923984	0.22749	123	П.	•		•		100 4 of 8
CONTRACTOR OF THE OWNER	29 Nifediaine	1736	4	Phanes, San 14, 17	134469225	C25H20N80	M-H	429.22974	429.22978	0.08529	121	10					100 5 of 8
Data Heview >	30 Lesetan	17.46	1281	Prenez.San28.18			M-H	429.23914	429,23975		2		•				100 5 017
Sample View	31 Telmiserten	1821	C	Pharma_Sam28_19			M-H	429.23974	429.23967	0.29658	1				•		100 4 of 6
Compound View	32 Diseatan	1921	1000	Prense SendC_20			M-H	429.23974	479,25987	0.29635	4	- 2					100 3 46
and the second s	33 Tancollen	19.74	7 4	Phanes Samit 31	48937415	C25H28N8O	34+8	120 2 3911	129,24085	072916	2	- D.					100 1 df7
Comparative View	Corporat Details		10.00														* 1
Qualitative View	Quit Fait	e (w) z	< aut	- 144													<b>E A</b>
ort Viewi	Interestien Wit 18:521	4 11 I		Allectope	Pharms 2	Sam20 10			5	an #: 2116-2128	10. 38.	90.81 - 90	AVE. \$3				
Local Method	513	12 543-636.74		Multi-Intoper		+ # EBI FLMAVO	(100.00-10	00.00									
	APT 25	17647118 H00.08	100	#1:429.23074 #2:436.23698	100-3	Ĩ		10									
Acquisition	100	1		#1:436,24000	80-												
Quantitation	2.10			Ab 2012/02/	60-												
Proceeding	3 70-		100	the number of the other states of the states of the states of the state of the state of the state of the states of	2 40	429				1							
Compounds	24-		12000	*5:43124641	1 20-	0.000			1				+5			18	
QAQC			1.5	#6 432 34400	1 .1	429.17	429,47		430,18	43.29		30.91 43	1.17		4	11.92 432.17	_
Contraction of the second	-			#7,432,34963	100-												
Groups					A 80-												
Intel Seq					60-												
Reports	- longers	harment			40-					2							
		firmini .			20-				125				84			26	
pibilizes	ra/z 42	9,33874			64	1			-		1000						
eysis:	April 17, 10,52 Artin 105436706	:			425	0	429.5	43	0.0	438.6	niz	431.0		431.5		432.0	432.5
Par se canada da se	Compound Details	in the second second															



#### Irbesartan std at 40ppt

1+ 11++ Tech Halp 3 - 11 11 11 11 11 11	- 1 - 回知 相子	A12.018													0.	ot tree status). User alle	utive O
knalysis • •	Data Beakw - Flas		1.00														
Datab View	Corporate			emple Results													* *
A COMPANY OF	() Compound	Expected RT	- 7	1 Filenarise	Aree	Ferrale	Adduct	m/c (Expected)	m/z (Apent	w/s (Detalppre)	Active	Excluded	PK	. P	Carlini	lootapic Pottern Score	No Nembo
Samples		5 *			in .	5 . •	.6 4	5 .	5 .	ð= =			5 -	8 4	4	-	·
Auto Semples	35 Flucentine	16.36		7 PhanesSan35,30	882945578	C25H28N80	M-H	1286.239718	129,23987	0.29858	125	E) .				- 14 - 14 - 14 - 14 - 14 - 14 - 14 - 14	100 1 of 6
Hoforence Sample	27 Serbaine	1671		Prema SemilC 21	98957415	C25H29N60	14-11	425.23974	429.34065	072516	121						100 S of 7
Threshold Samples	28 Tetrination	10.51	R	Pharma_Std1_05	1397613	C/3H28N80	M-H	429.23914	47925982	-0.21029	12	10					100 1 07 5
STATISTICS OF THE OWNER.	29 Mindare	17.36		D Pranta Shit 04	1256125	C25H28N60	M-H	425.23974	479,22985	-8.10989	15	E					100 3 of 2
Cata Neview 🗲	30 Lesartan	17.46	1	1 Prema Stat.05	3483897	C25H28N80	1d-H	42923914	429-23956	-841238	121	10					100 3 of 3
Sample View	31. Telmiserton	1821	91	2 Pharma_Std2_06	11379462	C25H28NeO	M-H	429.23974	429.23058	-8.94129	12	13					100 4 of 4
	32 Eberarten	1831	1	3 Phenne, Std2, 07	10718935	C25H25N9O	M-H	429.23974	429,23965	+8.19929	12	- 10					100.4 df 4
Compound View	H Tancalen	19.74	1	A Pharma Stat 08	10913584	C25H20N8O	M-H	428 23978	12933958	+6.24129	2	11					100 A of 8
Comparative View	Compoond Detain																* 1
Qualitative View	Ques Feak	a (#)	a    a	atips													* 4
sort View	Interaction INT 18:1211	4 14	•	Allietope	£				5	an *: 2097-2133	HT. 18.	- 18.85	10. 37				
			110	Wulti-Intoper	Fhama F. FTMS	+ a ESI Full me	100 10-10	800.000									
Local Method	971 cr 111-1	1.52 DBI 124.80	16	#1:479.23074	1. 1.	429,17											
Acquisition	100-1	174821-28 16-08	112	#2: 436 24000	100												
and Assessment and the second			112	#1:40124640	80-												
Quartifiation	2.00	1			60-						72						
Proceeding	1.	and the second			2 40-3					11,223					430.91 431	431.24	
Compounds	3 10 k	1.1.1.			1 20-		429.27			430.4	8				10000	-3	
	1				1 .3		the second	429.6	1	429,98		430.4	19	430	.84	431_18431_36	-
and the second s		- Ballalah			100-												
QAQC					3 100 3												
and the second s	*				2 7	429 23974											
dvdc.	3 4				a 40	429.23974											
QAQC Groups Jutel Seg	100				a 80-	429.23974					17						
QAQC Groups Intel Seg Reports	10-10-10-10-10-10-10-10-10-10-10-10-10-1					429.23974					R						
QAQC Groups Intel Seg Reports		in Intel			60-	429.23974				430 5452	6					<b>K</b> 3	
QAQC Groups Jutel Seg Reports	10-10-10-10-10-10-10-10-10-10-10-10-10-1				00 40 10 10 10 10 10 10 10 10 10 10 10 10 10	429,23974	2	4286	4218	430.243	6	438.4	430.6	430.8	4910		



## Sertraline in sample extract

bien Jook Unip	1 回知 計算中	414-0180	0												( two data) Cher stellars 1 🕐
alysis • •	Data Review - Pha	ma, Cal. P													
Reb.h View	Corporate	- 3 ·	Sample Results												* 3
- CONTRACTOR	1 Compound	Expected &F	P Filenome	Area	Fernale	Adduct	m/z (Expected)	m/s (Apex)	m/z (Detaippen))	Active	Excluded	, PK	P.	Cartheri	Sotopic Pattern Score (N) Numb
Samples		5 *		. b *	5 . *			5 .	÷ •			ð= =	5 ×	4 .	
Auto Senglies	25 Hallperido	11.86	1 Pharway, Bit, 10	N/C			206.08104	N,G	NE	王	12				N/A
Ioforence Sample	22 Sildenarii	14.85	2 Perma Bik 15	8/5			30638138	NF	NIT	- Ri	11				N/A
hreshold Samples	25 Parcentre	1421	5 Pharma,SamD	18 9394224	CLIHLTCUN	M+H	306.58128	\$35 (\$10)	-018340	- W.	12				100 9 4
A PROPERTY AND	24 Featenadise	15.55	4 Pranta SanD		CITHI7CUN	M+H	306.581.04	305.0809.3	-0.48152	21					100 B of
italievien >	25 Anitipylice	1570	5 Prema.San2		C17H170294	M-H	30638138	30518096	-038181	181	12		•		100 9 of
ample View	25 Fluoretime	15.26	5 Pharma_Sam2	700 N 102 N 100 I	C17H17CQN	M-H	306.08108	306.881.85	-0.08270	- M.					100 @ of
nespound View	27 Settal te	1671	7 Pherma Sendi		CLTHITCUN	M-H	306.95108	305.55095	-0.38181	8			•	•	100 9 4
ongerative View	18 Tethinafise	18.89	I Pranus Sand	: 31 7#18969	CLIMITIN	M-H	306.58110	335.04044 H	-0.00101	2		•	•		100 P.df
cal Method cquisition Nocessing Compounds QAQC Groups Juitel Seg oports	All a series more than a series of the serie	504979.59 507985-65	Nult-Intopet 41: 506 00106 42: 507 07817 45: 307 09444 40: 308 07817 45: 308 08789 45: 308 08799 45: 308 08149 47: 318 07558 75: 318 08464 47: 511 07854		306.21		8 872 <sup>2</sup> 117	28 388.07	*1 -5 -102 A1	ş 30	5 18.87	309.15	3489	'8 7 1 <u>For 6</u> 21	0.24 310,87 311 13 311 24
addiene	10.2.35	+	1	- 01	306.0	306.5	307.0 3	87.5	348.0 30	85	0.680	309		de la	318.5 311.0



### **Paroxetine in sample extract**

A NOT CONTRACT OF A DESCRIPTION OF A DES																	1++-(-05-)
e lies Joch Heip															Beat	(frite clate) (Der	ination: 🕖
) · · · · · · · · · · · · · · · · · · ·	1 回知計報中	● (赤空) 場	100														23
nalysis — •	Data Review - Ftu	erna, Gall, P															
Debb View	Companya	+ 3	- 5	imple Results													**
A STATE OF STREET	Compound	Expected 87	- 1	1 Filename	Aree	Fortale	Adduct	m/z (Expected)	m/s (Apex)	w/c (Detaipper)	Active	Excluded	PK	P	Cantern	Exetopic Pattern S	core (10 Nami
Sampleo		5 *			b •	5 1			5 .	6 .	*		ð	5 -	b	-	·
Auto Semples	17 Propisnoloi	12.66		Phanes, Rit, 1d	19332	CLINHZOPHOL	M-H	880.15000	320.15064	0.25882	2				-		0 1001
Reference Sample	18 Cielopere	1347		Pierres Bik 15	N/F			33015000	NF	NIT	95	11					N/A
Threshold Samples	10 Placamida	13.59	1	Pharma, SamilA, 18	291819	CL9H20PVOS	M-H	55015000	\$5115002	0.07585	100	12					11 100
Sector Conceptor and the local division of t	29 Cycloine / Mars	ine 13.85	131	Phanes, Sani 3, 17	238863	C19HZ0RV03	M-H	22015000	320.15088	0.25682	21	121					II 1 of 2
Cata Neview	21 Haloperidol	13.96		Prama_San18_18	1034882	C19H20PN08	M-H	3301,5000	330,54990	-0.29579	121	10					100 2 of 3
Sample View	22 Sildenafil	14.85	1	Pharma_Sam28_19	977548	C19H20PN08	M-H	3301,5000	330,54947	-0.38823	(N)	0					80,247
	23 Parcentine	14.81	1	Pherma Sam31, 20	1409317	C19H20PN05	M-H	33013000	330.24996	-0.11097	18						100 Juf?
Compound View	21 Feathraine	15.55	214	Phanes Samit: 31	3613991	CLENZOPNOS	M-H	23015000	830.15065 H	0.16638	2	- []	•	•			100 3 of
Comparative View	Corporat Detain																
Qualitative View	Spins Falk	*	A 10	- 4444													W 2
ort View	Parastra IC: 16.0	4 14	•	Allietope	Pharma	San28 19			50	at #: 1703-1714	HT 14.0	- 14.96 A	0.12				
Local Method		14.50		Wuit-Isstoper		+ a ESI Full roo	\$100.80-10	00.00									
FOCS INVEDIOR	MA. Art	8775+6.23 261500.88		41:338 19000	100-												
Appublies	100-314			42:331.15535	80-												
Quanification				40:302.25850	1 1 1 H	2					2						
Contraction of the second second	3.4				60-	8											
Proceeding	100 miles				g 40	100.00					133	1.21			33	12.02 332.10	
Composinda	1 40-				1 201	338.18	330.23 33	0.34		330.98 331.0	19 1 33	1.25		331.78	331.89	1.	
QAQC .	2 1-				2 0-3	338,19000	alu -				halle					A ALEXANDER	
and the second se	-				3 100-	339,19996											
Groups					a 20-												
and the second second					60-												
Intel Seg	-				- 10 H						92						
and the second second	=				40-1												
Intel Seg		Tanni			40-											43	
Jutel Seg Reports					40-3 20-3 0-3						ſ					A3	



### Sildenafil in sample extract

1 🖬 🖬 💷 1 🗃 🖓		0												( troe ctatue ) Uner abscations : 😗
nalysis 🔹 !	Data Review - Pharma Cal J*													
Butch View	Corporation	Sample Results												••
	Compound Expected #1	ff Fictoric	Arto	Fornale	Adduct	m/s(Expected)	m/s (Apex)	m/c (Detaipper()	Active	Excluded	PK.	P.	Canher	botopic Pattern Score (N) Numb
Samples		5 *			* *		5 .	ė •			ðr . +	21. 1	5. *	· · · ·
Auto Sergies	17 Proprietalia 1286	1 Pharma, Bit, 1d	14.17			-575.31.220	N/F	104	2	-				N/0.
Hoforence Sample	18 Olekoperte 1347	2 Pharma Bik 15	N/F			475.21.229	NF	NE	190	12				N/A
Threshold Samples	18 Plecamide 1535	5 Pharma_SamUA_18	058561	CZIHS0N8048	M-H	475.21.228	47521194	-0.53749	100	<b></b>				197 3 cf 4
CONTRACTOR OF THE OWNER.	20 Cycloire / Marsine 13.85	4 Phanes, Sani A, 17	620122	C22H20N8O45	M-H	475.21.228	475,21194	-0.53749	2	10				100 1444
Data Heview 🗲 🗲	21 Hatsperidol 1396	5 Pranka.Sam28_18	696111	C22H30N8045	M-H	475.21.228	47521194	-0.53749	10					92 3 of 4
Sample View	22 Sidenarii 1485	5 Pharma_Sam28_19	516344	C22H30N6045	M-H	475.21228	475,22214	0.16882	10					300 3 of 4
Compound View	23 Parcentre 1421	7 Planta,San3C,33		CZ2H30N8045	M-H	475.21.228	475,21178	-0.51858	10					10 2 d 4
and the second se	24 Fearterative 1555 7	8 Phanes SavidC JL	586700	C23H8098O45	M+H	675.31.238	475.31170	-1.05128	20					41 3 44 4
Comparative View	Corporat Details	151												·
Qualitative Viere	Quisting + W R	autups +												<b>T A</b>
ort Viver	4 11 F	Allectore					5:0	* * 1697-1706	10. 14.75	- 14.80 /	1 10			61 V.S
	Contrast Million (a la la casa	Wulti-Intoper		Sam20 15 + p EBTFut mp)		100.000								
Local Method	87, 14,38 AA, 636112 AT	#1:4T5.21220			A									
A sec details	AP1 186842.30 304 307 30	42:476.21554	43	1	-	10								
Acquisition	100	+1-411,20807	30-		475.24									
Quantitation	2.00	AL 417,21841	1. 1. 1.			+								
Proceeding	3 10-	Persitations	20-	475.17					72					477 26
Compounds	24-		1 10-	410.01	475.23	16393				25.53		100	6	3
QAQC			18.00		about	475.6	5 475.80	478.17	1 1	2.24		476.	14	and a
Que transmission	-		1 43-											
Groups	2		14											
Intel Seg	- H		30-											
Reports	Harris Carrow		20-	1					42					
	- 4 19			1					-					#3
	87(mini mi/1:475,21220		10-	1					1					and the second second
and descent from									1					
uhitim	April 27, 14,84		0.7	475.0 475.2	475	4 475.6	475.8	476.0 42	16.2	478.4	47E.E	476.8	477.0	477.2 477.4



## **Results from Q-Exactive screening**

- Chromatographic peaks and isotopic pattern matches have been reported for all 39 compounds, in both matrix samples and standard solutions
- Mass accuracy was excellent, typically < 1ppm and the maximum error observed was 2.25pm. This was using no lock mass.
- By using high resolution (140,000 @ m/z 200) the fine isotopic structure could be observed to further confirm identification.
- High resolution also resolved isobaric species in the background, maintaining the excellent mass accuracy



## **Summary & Conclusions**

- Passive samplers are an effective investigative tool
- Detects episodic changes in environmental contaminant concentrations often missed with spot sampling
- Proven to accumulate a wide variety of polar pesticides
- TWA estimates of concentration obtained from calibration
- Use of Q-Exactive resulted in increased sensitivity & confidence in identification of pharmaceutical residues



# Thank you for listening

